



Oncology Institute of Southern Switzerland (IOSI)
in collaboration with Institut Curie - Department of Drug
Development and Innovation (D3i)

Drug Development in Oncology 2024

**Ospedale Regionale di Bellinzona e Valli,
Bellinzona (Switzerland)**
Auditorium (Building F)

20, 21 and 22 June 2024

The event will be held in hybride mode, online and in-person



Programme

[Link to registration](#)

June 20, 2024
from 14.00 to 18.00



1st day, Thursday 20 June 2024

14h00 **Registration**

14h30 **Introduction & Training information**

Anastasios Stathis, CH

Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland

Christophe Le Tourneau, FR

Institut Curie, Paris, France

14h45 **Drug development: from bench to clinical trials**

Miguel Quintela, ES

Spanish National Cancer Research Center (CNIO), Madrid,
Spain

15h15 **Treatment & Clinical Development Strategies in
Oncology**

Christophe Le Tourneau, FR

Institut Curie, Paris, France

15h45 **Coffee break**

16h15 **Regulatory aspects**

Michaela Gutacker, CH

Cantonal Ethics Committee, Bellinzona, Switzerland

16h45 **Ethical aspects in early clinical trials: the Ethics
Committee and patients perspective**

Beatrice Gai, CH

Cantonal Ethics Committee, Bellinzona, Switzerland

Cristiana Sessa, CH

Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland

17h30 **Discussion & Questions**

All

[Link to registration](#)

June 21, 2024
from 09.00 to 18.00



2st day, Friday 21 June 2024 - morning

09h00 **Welcome & coffee**

09h30 **Dose finding studies in Oncology**

Irene Braña, ES

Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Spain

10h00 **Dose finding studies: Focus on immunotherapy**

Emiliano Calvo, ES

START Madrid, Centro Integral Oncológico Clara Campal
(CIOCC), Madrid, Spain

10h30 **Specificities of Early Phase clinical trials of Cell
Therapies**

Martina Imbimbo, CH

Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland

11h00 **Advances in liquid biopsies**

Davide Rossi, CH

Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland

11h30 **Drug screening in cell lines and organoids**

Francesco Bertoni, CH

Institute of Oncology Research (IOR), Bellinzona,
Switzerland

12h00 **Discussion & Questions**

All

12h30 **Lunch break**

2st day, Friday 21 June 2024 - afternoon

- 13h30 **What is an acceptable safety profile in Drug Development?**
Anastasios Stathis, CH
Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland
- 14h00 **Evaluation of Response to treatment and new response criteria**
Martina Imbimbo, CH
Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland
- 14h30 **Drug-Drug interactions**
Alessandro Ceschi, CH
Istitute of Pharmacological Sciences of Southern
Switzerland, EOC, Bellinzona, Switzerland
- 15h00 **Discussion & Questions**
All
- 15h30 **Coffee break**
- 16h00 **Neutrophils in cancer: heterogeneous and multifaceted**
Arianna Calcinotto, CH
Institute of Oncology Research (IOR), Bellinzona,
Switzerland
- 16h30 **Human pluripotent stem cells**
Arianna Baggiolini, CH
Institute of Oncology Research (IOR), Bellinzona,
Switzerland
- 17h00 **Mechanisms of resistance to CART therapy**
Patrizia Porazzi, USA
University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 17h30 **Discussion & Questions**
All

[Link to registration](#)

June 22, 2024
from 09.00 to 15.30



3rd day, Saturday 22 June 2024 - morning

- 09h00 **Welcome & coffee**
- 09h30 **Antibody Drug Conjugates in Oncology**
Anastasios Stathis, CH
Oncology Institute of Southern Switzerland, EOC,
Bellinzona, Switzerland
- 10h00 **Bispecific Antibodies in Oncology**
Irene Braña, ES
Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Spain
- 10h30 **Precision medicine Trials**
Christophe Le Tourneau, FR
Institut Curie, Paris, France
- 11h00 **Generation of Real Word Evidence**
Martina von Meyenn, CH
F. Hoffmann – La Roche, Basel, Switzerland
- 11h30 **Discussion & Questions**
All
- 11h45 **Lunch break**

3rd day, Saturday 22 June 2024 - afternoon

- 12h45 **Biomarkers of efficacy to new drugs**
Gaia Griguolo, IT
University of Padova and Veneto Institute of Oncology,
Padova, Italy
- 13h15 **National initiatives for molecular screening in Oncology**
Maud Kamal, FR
Institut Gustave Roussy, Villejuif, France
- 13h45 **PK/PD analyses-case studies**
Markus Jörger, CH
Kantonsspital St. Gallen, St. Gallen, Switzerland
- 14h15 **Data Intergration aspects**
Luca Mazzearella, IT
European Institute of Oncology (IEO), Milan, Italy
- 14h45 **AI to guide treatment decision**
Istvan Petak, USA
Genomate Health, Cambridge, Massachusetts, USA
- 15h15 **WRAP UP**
All

We thank our sponsors:

Main sponsor

AstraZeneca 

Sponsor

AMGEN

 **BeiGene**



janssen  **Oncology**
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Lilly

 **MSD**

